0 items

in your cart
$0.00

Prescription Drug Search

Strengths available for Amitiza:

Amitiza 8mcg
Amitiza 24mcg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Amitiza:

  • Algeria
  • Anguilla
  • Antigua and Barbuda
  • Australia
  • Azerbaijan
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Bolivia
  • Bulgaria
  • Chile
  • Cuba
  • Czech Republic
  • Denmark
  • Ecuador
  • Estonia
  • European Union
  • Finland
  • Guadeloupe
  • India
  • Iraq
  • Italy
  • Japan
  • Korea, Republic of
  • Kuwait
  • Latvia
  • Luxembourg
  • Moldova, Republic of
  • Morocco
  • Norway
  • Paraguay
  • Philippines
  • Romania
  • Russian Federation
  • Seychelles
  • Thailand
  • United Kingdom, UK
  • United States, US
  • Vietnam
View All Countries

Latest news releases on Amitiza:

Sucampo Presents Data for AMITIZA(R) in the Treatment of Moderate to ...  - CNBC

BETHESDA, Md., May 20, 2012 (BUSINESS WIRE) -- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA(R) (lubiprostone) for the treatment of ...

Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction (OBD) - Yahoo Finance

About AMITIZA for Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C) AMITIZA is a chloride channel activator indicated for the treatment of CIC (24 mcg twice daily) in adults and for IBS-C (8 mcg twice ...

Sucampo Presents Data for AMITIZA® in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C) - Yahoo Finance

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP - News) today announced the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA ® (lubiprostone) for the treatment of irritable bowel syndrome with ...

Sucampo Presents Data for AMITIZA in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation - Benzinga

Sucampo Pharmaceuticals (NASDAQ: SCMP) announced Sunday the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA (lubiprostone) for the treatment of irritable bowel syndrome with constipation at Digestive Disease ...

Sucampo Pharmaceuticals, Inc. : Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction (OBD) - 4-traders (press release)

The incidence rates of severe nausea were 1.4% for placebo-treated patients and 0.9% for lubiprostone treated patients. About AMITIZA for Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C) AMITIZA is a chloride ...

Sucampo Presents New Phase III Data from Opioid-Induced Bowel Dysfunction Study - Genetic Engineering News

Lubiprostone is a prostone-based chloride channel activator discovered by Sucampo and already approved as Amitiza for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Back in February ...

Gaithersburg drug-maker signs deal for European market - Maryland Community Newspapers Online

Sucampo already has marketed the drug as Amitiza for several years to treat chronic idiopathic constipation and irritable bowel syndrome with constipation. BioElectronics reported that it has received regulatory clearance to market its ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK